111, Inc. (YI) Q4 2024: Operating Expenses Cut 50% Drives First Annual Operating Profit
111, Inc. achieved a historic milestone with its first-ever annual operating profit and positive operating cash flow in 2024, driven by aggressive cost management and AI-powered operational efficiency. Despite a challenging macroeconomic environment and declining revenues, the company’s technology investments and supply chain innovations underpin a durable competitive advantage. The outlook focuses on scaling AI integration and expanding fulfillment infrastructure to sustain growth and margin improvements.
Summary
- Cost Efficiency Transformation: Operating expenses halved in Q4, underpinning a major profitability turnaround.
- Technology-Led Supply Chain Innovation: AI and shared inventory systems expanded product availability and optimized logistics.
- Strategic Growth Focus: Plans to scale fulfillment centers and deepen AI integration aim to drive sustainable margin expansion.
Business Overview
111, Inc. is a tech-enabled healthcare platform primarily serving China's pharmaceutical distribution and retail pharmacy sectors. It generates revenue through its B2B wholesale segment supplying drugs to pharmacies and a smaller B2C retail segment. The company’s business model leverages digital technologies and AI to connect upstream pharmaceutical suppliers with downstream pharmacies and consumers, while optimizing supply chain and marketing operations.
Performance Analysis
In the fourth quarter of 2024, 111 reported net revenues of RMB 3.8 billion, down 6.3% year-over-year, reflecting macroeconomic headwinds and industry-wide retail pharmacy sales contraction. Gross segment profit declined 5.5%, but the company achieved a significant reduction in operating expenses, which fell 50.1% to RMB 209.8 million, or 5.5% of revenues, down 470 basis points from the prior year. This drastic expense cut drove operating loss to just RMB 7.3 million, a 96.5% improvement from a RMB 206.5 million loss a year earlier. The non-GAAP loss from operations also improved by 95.8%, underscoring operational leverage gains.
For the full year 2024, revenues declined 3.7% to RMB 14.4 billion, with gross segment profit down 2.3%. However, operating expenses fell 31% to RMB 827.1 million, reducing the expense ratio by 230 basis points to 5.7%. This enabled the company to post its first-ever annual operating profit of RMB 2.1 million, reversing a RMB 350 million operating loss in 2023. Positive operating cash flow of RMB 263 million further validates the improved financial health. The company’s operational efficiency is a key differentiator, especially given its smaller scale relative to larger competitors.
- Expense Optimization: Selling, general, and technology expenses all decreased significantly as a percentage of revenues, reflecting disciplined cost control and digital automation.
- Supply Chain Enhancements: Expansion of fulfillment centers and a compound logistics network reduced delivery times and damage rates, improving customer service and cost structure.
- Technology Investments: AI-driven demand forecasting and inventory sharing increased SKU availability by 33,000 and improved forecasting accuracy from 71% to 82%, boosting gross merchandise volume and user metrics.
Overall, the quarter and full-year results demonstrate 111’s ability to navigate a difficult market through strategic cost management, operational digitization, and supply chain innovation, laying a foundation for sustainable growth.
Executive Commentary
"2024 was a year of significant challenges stemming from the macroeconomic pressures and ongoing healthcare reforms. Yet, we delivered our first-ever operational profitability and positive operating cash flow, an important milestone in our company's history. This solid performance is a direct result of our diligent execution of strategic initiatives to boost operational efficiency and cement us as one of the most efficient healthcare platform operators in the sector."
Junling Liu, Co-founder, Chairman & CEO
"We believe the key driver behind our first-ever annual operating profit and positive cash flow is our relentless efforts to improve operation efficiency. While maintaining our revenue scale, our operating expenses decreased 230 basis points year-over-year in 2024. Our accounts stable days and inventory turnover metrics reflect strong working capital management, and we are confident this foundation supports sustainable profitability in 2025 and beyond."
Luke Chen, CFO, 111’s Major Subsidiary
Strategic Positioning
1. AI-Driven Operational Efficiency
111 has embedded AI and digital technologies deeply into its supply chain and customer engagement processes. The company’s AI-powered demand forecasting improved accuracy to 82%, enabling better inventory allocation and reducing stockouts by half. AI also supports pricing optimization and marketing campaigns, fueling higher user retention and transaction volumes. This technology backbone differentiates 111 in a fragmented and cost-sensitive market.
2. Expansion of Fulfillment Infrastructure
The company’s compound logistics network now operates 28 transportation routes linking five major super hubs, enabling delivery to over 300 cities within 24 hours and nationwide within 72 hours. Seven new fulfillment centers went online in Q4, with plans to add at least 15 more in 2025, focusing on underserved provinces. This expansion supports faster delivery, lower damage rates, and cost reductions through regionalized inventory management.
3. Franchise Warehouse Model and Shared Inventory
111’s innovative franchise warehouse model integrates third-party fulfillment centers into its network, expanding product selection with lighter asset intensity. Shared inventory technology allows real-time visibility and elastic response to demand across partners, enhancing product availability by RMB 290 million worth of stock and increasing SKUs by 33,000. This scalable approach improves margins and customer satisfaction.
4. Customer Engagement and Demand Stimulation
Initiatives such as weekly flash sales and the "Together We Grow" program target mid-tier chain pharmacy customers to increase wallet share and loyalty. AI-driven marketing and online-offline integration, including brand live streams, enhance customer experience and drive transaction growth. December’s gross merchandise volume rose 17% month-over-month, with average revenue per user and order increasing by 18% and 14% respectively.
5. Strategic Partnerships and Market Positioning
111 aims to deepen collaborations with upstream pharmaceutical companies and downstream pharmacies to facilitate drug distribution and promotion. The company leverages its platform to replace traditional, labor-intensive drug promotion with AI-powered digital solutions, aligning with ongoing healthcare reforms focused on cost reduction and efficiency. This positions 111 as a key partner in China’s evolving pharmaceutical ecosystem.
Key Considerations
111’s 2024 performance reflects a strategic pivot towards operational efficiency and technology-driven scalability amid a challenging healthcare market environment.
Key Considerations:
- Macroeconomic Headwinds: Slower healthcare spending and intensified pharmacy competition pressured revenue, underscoring the importance of cost control.
- Digital Transformation as a Differentiator: The company’s AI and digital infrastructure investments have created a competitive moat in forecasting, inventory management, and customer engagement.
- Supply Chain Scalability: Expansion of fulfillment centers and logistics networks enhances service quality and cost efficiency, critical for future growth.
- Profitability Sustainability: Operating expense discipline and working capital management underpin confidence in sustaining profitability despite revenue softness.
- Regulatory Environment: Ongoing healthcare reforms introduce uncertainty but also long-term opportunities for well-positioned digital platforms like 111.
Risks
Risks include continued macroeconomic weakness dampening consumer healthcare spending and retail pharmacy sales, potential delays or uneven implementation of healthcare reforms, and intensifying competition from larger, state-owned players. Regulatory changes could also impact business operations or profitability. The company’s success depends on its ability to maintain cost discipline and execute technology-driven growth initiatives in this evolving environment.
Forward Outlook
For Q1 2025, management anticipates continued focus on operational efficiency and expansion of the fulfillment network, with ongoing investments in AI to enhance supply chain and customer engagement. While specific revenue guidance was not provided, the company plans to leverage its digital platform and franchise model to grow product assortment and customer base.
- Expansion of at least 15 additional fulfillment centers to improve delivery speed and coverage.
- Increased AI integration across procurement, pricing, and customer service to drive operational leverage.
Management highlighted that despite challenges, the company is well positioned to capitalize on long-term structural trends in China’s healthcare market, including pharmaceutical sales shifting to retail pharmacies and rising healthcare demand from an aging population.
Takeaways
111, Inc.’s Q4 and full-year 2024 results mark a significant inflection point, demonstrating the company’s ability to achieve profitability through disciplined cost management and technological innovation in a difficult market.
- Operational Efficiency as Core Competency: The 50% cut in operating expenses in Q4 and 31% reduction for the full year are central to the profitability turnaround, reflecting deep organizational focus on granular cost control and digital automation.
- Technology and Supply Chain as Growth Engines: AI-powered forecasting, shared inventory, and a rapidly expanding fulfillment network provide scalable platforms to improve product availability, reduce costs, and enhance customer experience.
- Future Growth Hinges on Execution: Sustaining profitability and scaling revenue will depend on successful expansion of franchise fulfillment centers, deeper AI integration, and navigating regulatory uncertainties in China’s evolving healthcare landscape.
Conclusion
111, Inc.’s first-ever annual operating profit and positive operating cash flow in 2024 validate its strategic emphasis on AI-driven operational efficiency and supply chain innovation. While revenue pressures persist amid macro and industry headwinds, the company’s scalable platform and disciplined cost structure position it well for sustainable growth and margin expansion in 2025 and beyond.
Industry Read-Through
111’s results underscore the critical role of digital transformation and AI in China’s healthcare distribution sector, where rising competition and regulatory reform pressure traditional pharmacy models. The company’s success in operationalizing shared inventory and franchise fulfillment networks offers a blueprint for peers seeking scalable, asset-light growth. Its emphasis on AI for demand forecasting and customer engagement signals broader industry shifts towards data-driven efficiency and precision marketing. Investors and operators should monitor how digital platforms leverage technology to consolidate fragmented pharmacy markets and capitalize on structural shifts in pharmaceutical sales.